Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;28(8):e220094.
doi: 10.3201/eid2808.220094.

Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches

Lisa E Manhart, William M Geisler, Catriona S Bradshaw, Jørgen S Jensen, David H Martin

Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches

Lisa E Manhart et al. Emerg Infect Dis. 2022 Aug.

Abstract

Since Mycoplasma genitalium was identified 40 years ago, much of the epidemiology has been described, diagnostic tests have been developed and approved, and recommended treatment approaches have been identified. However, the natural history remains incompletely understood, and antimicrobial resistance has rapidly increased. This review summarizes evidence published since the US Centers for Disease Control and Prevention 2015 Sexually Transmitted Diseases Treatment Guidelines. Data on sequelae remain insufficient, macrolide resistance is common, and fluoroquinolone resistance is increasing. Potential benefits of testing and treatment include resolving symptoms, interrupting transmission, and preventing sequelae. Potential harms include cost, patient anxiety, and increasing antimicrobial resistance.

Keywords: Mycoplasma genitalium; antimicrobial resistance; bacteria; bacterial drug resistance; natural history; sexually transmitted infections.

PubMed Disclaimer

Figures

Figure
Figure
Results of systematic search for literature on Mycoplasma genitalium (January 1, 2015–November 30, 2021). STI, sexually transmitted infection.
See this image and copyright information in PMC

References

    1. Bachmann LH, Kirkcaldy RD, Geisler WM, Wiesenfeld HC, Manhart LE, Taylor SN, et al. ; MAGNUM Laboratory Working Group. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. Clin Infect Dis. 2020;71:e624–32. 10.1093/cid/ciaa293 - DOI - PMC - PubMed
    1. Chambers LC, Morgan JL, Lowens MS, Robinson TS, Romano SS, Leipertz GL, et al. Cross-sectional study of urethral exposures at last sexual episode associated with non-gonococcal urethritis among STD clinic patients. Sex Transm Infect. 2019;95:212–8. 10.1136/sextrans-2018-053634 - DOI - PMC - PubMed
    1. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015;61:418–26. 10.1093/cid/civ312 - DOI - PubMed
    1. Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility—a prospective study. Fertil Steril. 2008;90:513–20. 10.1016/j.fertnstert.2006.12.056 - DOI - PubMed
    1. Clausen HF, Fedder J, Drasbek M, Nielsen PK, Toft B, Ingerslev HJ, et al. Serological investigation of Mycoplasma genitalium in infertile women. Hum Reprod. 2001;16:1866–74. 10.1093/humrep/16.9.1866 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources